LATEST NEWS
HOTH THERAPEUTICS, INC. TO PRESENT AT THE THINKEQUITY CONFERENCE
NEW YORK, April 30, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and...
read moreHoth Therapuetics Inc. Announces the Addition of Dr. Richard D Granstein, M.D. to the Company’s Technology Advisory Board
NEW YORK, NEW YORK October 16, 2017 /PR Newswire/Hoth Therapeutics Inc., a Nevada corporation (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
read moreHoth Therapuetics Inc. Announces the Addition of Dr. Andrew Herr to the Company’s Technology Advisory Board
NEW YORK, NEW YORK September 5, 2017 /PR Newswire/ Hoth Therapeutics Inc., a Nevada corporation (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
read moreSPHERIX INC. ANNOUNCES CLOSING OF THE DEAL WITH HOTH THERAPEUTICS
Spherix Incorporated Acquires 6,800,000 shares of Hoth Therapeutics New York, NY July 3, 2017 /PR Newswire/ Spherix Incorporated (NASDAQ: SPEX) reportedtoday, following the disclosure made June 20th 2017, that the Company has closed the transaction with Hoth...
read moreSPHERIX ISSUES LETTER TO SHAREHOLDERS
New York, NY, June 28, 2017 /PRNewswire/ Spherix Incorporated (NASDAQ: SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, today issued a letter to shareholders. Dear Spherix...
read moreSPHERIX INC. ANNOUNCES DEFINITIVE TERMS REACHED TO ACQUIRE CONTROLLING INTEREST IN HOTH THERAPEUTICS, A BIOPHARMACEUTICAL COMPANY DEVELOPING ITS BIOLEXA PLATFORM TO TREAT SKIN ILLNESS SUCH AS ECZEMA.
Hoth’s BioLexa platform uses its proprietary technology to treat eczema without the use of traditional topical steroids. New York, NY June 20, 2017 / PRNewswire/ Spherix Incorporated (NASDAQ: SPEX) announced today that the Company has negotiated definitive terms to...
read more